Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies & Clinical Trials Insight 2031

May 2026 | 1200 pages | ID: G2CEF68CC3B8EN
Kuick Research

Abstracts

Findings & Highlights:

• Global Multispecific Antibodies Market Opportunity: USD 60 Billion By 2031
• Global Multispecific Antibodies Market Growth 2020 - 2025: Around 40% CAGR & 430% Absolute Growth
• Approved Multispecific Antibodies Dosage, Patent, Price & Sales Insight
• Global, Regional, Annual, Quarterly Sales Insight: 2020 Till Q1’2026
• Multispecific Antibodies Clinical Trials Insight By Company, Indication & Phase
• Multispecific Antibodies In Clinical Trials: > 750 Antibodies
• Bispecific, Trispecific & Tetraspecific Antibodies Clinical Trials & Sales Insight
• Competitive Landscape

Need For Multispecific Antibodies & Why This Report?

Multispecific antibodies, extending from standard bispecifics to the next generation of trispecific and tetraspecific antibodies, are quickly revolutionizing the therapeutic landscape. Through the ability to target multiple biological entities, this new approach can effectively address disease complexities such as tumor heterogeneity, immune evasion, and redundant signaling pathways. As current treatments based on a single biological target or even two targets continue to show challenges, multispecific antibodies could offer the next level of success in drug development.

In light of the increasing successes in developing bispecific antibodies, new opportunities arise for even more advanced and effective drug discovery and development. The inclusion of different mechanisms within a single therapeutic drug can lead to significant improvements in treating various diseases. In cancer, importantly, combining immune stimulation or immune modulation with tumor targeting can result in a more effective solution to existing treatment paradigms.

This report aims at offering a forward looking analysis of the new segment in the field of immunotherapeutic antibodies. In this case, rather than providing basic facts about this technology, the report is intended to show the areas of innovation, challenges, and the evolving competitive landscape in the development of advanced therapies.

We, at Kuick Research, have been one of the pioneers publishing reports dedicated to analyzing the global market for bispecific, trispecific, and tetraspecific antibodies over the last decade. The reason behind this lies in the considerable future market growth opportunity associated with the development of such molecules, which are expected to become one of the main drivers for next generation drugs.

Clinical Trials Insight Included In Report

Clinical development emerges as a crucial parameter for shaping the fate of multispecific antibodies. Although the current number of marketed multispecific antibodies is still relatively small, an impressive pipeline of molecules advances further in clinical trials – mostly in oncology and immunology indications.

The report delivers analytical insights about the clinical trial landscape, ranging from early phase trials to pivotal ones. It analyzes how the developers handle major difficulties associated with clinical development including dosing issues, safety concerns, and the use of biomarkers to select the right patients. In particular, special attention is paid to trials conducted in relapsed/refractory populations, wherein multispecific antibodies have to prove their clinical advantage.

These trials are examined in a variety of perspectives, such as the indication, the combination process, geographical spread, and stratification. Through an analysis of these trials in regard to their mechanism, trial design, and selection of targets, the report is able to give an indication on the likelihood of success and the development of new therapies.

Major Companies Active In R&D Of Multispecific Antibodies

The competitive environment in multispecific antibody space is dominated by both well-known pharmaceutical giants and cutting-edge biotech players. Big pharmaceutical firms like Roche, Amgen, and Johnson & Johnson capitalize on their experience in research and development, clinical trials, and commercialization to venture into more sophisticated multispecific antibody spaces, contributing to stability and certainty within the market.

Additionally, there is a rising trend of new biotech firms that innovate using their own platform technologies and new molecular structures. These innovative firms include Zymeworks, Alligator Bioscience, and ABL Bio. They are agile and their technological differentiators make them good collaboration partners and potential acquisition targets.

Technology Platforms, Collaborations & Agreements

Technological innovation plays an important role in pushing multispecific antibodies further since going beyond the bispecific approach brings with it difficulties related to stability, production, and safety. Proprietary technology platforms allow for developing antibodies with higher specificity and manufacturing efficiency. For example, QLSF Biotherapeutics has developed the TECAD (T Cell Engager with Co-Stimulation, Avidity Driven) platform for designing sophisticated multispecific molecules, while Amgen continues refining new antibody engineering processes using its BiTE platform.

Alliances and mergers are no less significant in advancing innovations in the multispecific antibody landscape. Such examples as collaboration between Boehringer Ingelheim and Simcere Pharmaceutical Group or Genmab acquiring Merus in December 2025 demonstrate how pharmaceutical companies can gain access to cutting-edge platforms while distributing risks.

In this report, we will analyze selected alliances, mergers, and licensing arrangements to show how deals are organized and what they say about future business trends.

Report Indicating Future Direction Of Multispecific Antibody Segment

The prospects for multispecific antibodies look extremely positive, backed by increased funding, pipeline developments, and ongoing innovations. With an ever-growing number of candidates progressing into advanced stages of development, the probability of obtaining regulatory approval in the coming years seems increasingly likely.

Multispecific antibody combinations are poised to make a name for themselves in this field moving forward, especially within oncology. The development of multispecific antibodies that can be used as part of combination therapies is becoming increasingly common, both as backbone treatment or as adjuvant to current treatments. There is also growth in the use of multispecific antibodies in autoimmune and inflammatory indications.

For investors interested in this sector, knowledge of innovation, development progress and positioning will prove crucial in making decisions. This report provides a curated view of these factors, enabling informed decision making.

Contents

1. RESEARCH METHODOLOGY

2. INTRODUCTION TO NEXT GENERATION MULTISPECIFIC ANTIBODIES

3. NEXT GENERATION MULTISPECIFIC ANTIBODY CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK

3.1 Current Market Overview
3.2 Future Commercialization Opportunity
3.3 Next Generation Multispecific Antibody Proprietary Technologies By Company

4. NEXT GENERATION MULTISPECIFIC ANTIBODY CLINICAL TRENDS BY INDICATION

4.1 Cancer
4.2 Hematological Disorders
4.3 Microbial Infections
4.4 Autoimmune & Inflammatory Disorders
4.5 Ocular Diseases

5. NEXT GENERATION MULTISPECIFIC ANTIBODY CLINICAL DEVELOPMENT & MARKET TRENDS BY REGION

5.1 US
5.2 Europe
5.3 China
5.4 UK
5.5 Japan
5.6 Australia
5.7 South Korea
5.8 Canada

6. APPROVED MULTISPECIFIC ANTIBODIES – CLINICAL OVERVIEW, PRICING, DOSING & SALES INSIGHT

6.1 Overview
6.2 Clinical Overview, Pricing & Dosage Insight
6.3 Sales Insight (2020 – Q1’2026)

7. GLOBAL MULTISPECIFIC ANTIBODIES CLINICAL TRIALS OVERVIEW

8. GLOBAL BISPECIFIC ANTIBODIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase-II/III
8.7 Phase III
8.8 Preregistration
8.9 Registered

9. MARKETED BISPECIFIC ANTIBODIES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

10. GLOBAL TRISPECIFIC ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II
10.6 Phase II/III

11. TETRASPECIFIC ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE

11.1 Preclinical
11.2 Phase I
11.3 Phase I/II
11.4 Phase II

12. COMPETITIVE LANDSCAPE

12.1 AbbVie
12.2 ABL Bio
12.3 Abzyme Therapeutics
12.4 Affimed Therapeutics
12.5 Akeso Biopharma
12.6 Alligator Bioscience
12.7 Amgen
12.8 APITBIO
12.9 Astellas Pharma
12.10 AstraZeneca
12.11 Aptevo Therapeutics
12.12 BioAtla
12.13 Biocytogen Pharmaceuticals
12.14 Biosion
12.15 CStone Pharmaceuticals
12.16 Diagonal Therapeutics
12.17 EpimAb Biotherapeutics
12.18 FutureGen Biopharmaceutical
12.19 Genentech
12.20 Genmab
12.21 Genor Biopharma
12.22 Gensun Biopharma
12.23 Harbour BioMed
12.24 IGM Biosciences
12.25 I-MAB Biopharma
12.26 ImmuneOnco Biopharma
12.27 ImmunoPrecise Antibodies
12.28 Innate Pharma
12.29 Innovent Biologics
12.30 Invenra
12.31 Johnson & Johnson
12.32 Kenjockety Biotechnology
12.33 LaNova Medicines Limited
12.34 Light Chain Bioscience
12.35 Linton Pharm
12.36 Lyvgen Biopharma
12.37 MacroGenics
12.38 Merck
12.39 Merus
12.40 ModeX Therapeutics (OPKO Health)
12.41 Molecular Partners
12.42 NovaRock Biotherapeutics
12.43 Numab
12.44 OPKO Health
12.45 Pfizer
12.46 Regeneron Pharmaceuticals
12.47 Revitope
12.48 Roche
12.49 Sanofi
12.50 Sichuan Baili Pharmaceutical
12.51 SystImmune
12.52 Virtuoso Therapeutics
12.53 Xencor
12.54 Y-Biologics
12.55 Zymeworks

List Of Tables

LIST OF TABLES

Table 3-1: Multispecific Antibodies FDA Designations (Orphan, Breakthrough Therapy & Fast Track)
Table 3-2: Global Multispecific Antibodies Market – Collaborations, License Agreements & Acquisitions
Table 3-3: Global Multispecific Antibodies Market – Emerging Startups
Table 3-4: Global Multispecific Antibodies Market – Investments

Table 4-1: Hematological Cancers – Approved Multispecific Antibodies
Table 4-2: Solid Cancers – Approved Multispecific Antibodies

Table 6-1: Approved Multispecific Antibodies
Table 6-2: Blincyto – Active Patents
Table 6-3: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
Table 6-4: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 6-5: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 6-6: Rybrevant – Premedication
Table 6-7: Rybrevant - Dose Reductions For Adverse Reactions
Table 6-8: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
Table 6-9: Lunsumio – Recommended Treatment Cycles
Table 6-10: Lunsumio - Recommended Premedications
Table 6-11: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
Table 6-12: Tecvayli - Dosing Schedule
Table 6-13: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
Table 6-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 6-15: Columvi - Premedications To Be Administered
Table 6-16: Columvi - Recommendations For Management Of Cytokine Release Syndrome
Table 6-17: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)


Table 6-18: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
Table 6-19: Epkinly - Dosage Schedule
Table 6-20: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
Table 6-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-22: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
Table 6-23: Talvey - Weekly Dosing Schedule
Table 6-24: Talvey – Biweekly Dosing Schedule
Table 6-25: Talvey - Recommendations For Management of CRS
Table 6-26: Talvey - Recommendations For Management Of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-27: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
Table 6-28: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
Table 6-29: Elrexfio - Dosing Schedule
Table 6-30: Elrexfio – Recommendations For Management Of CRS
Table 6-31: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
Table 6-32: Kaitani - Recommended Dose modifications
Table 6-33: Ordspono - Recommended Dose
Table 6-34: Ordspono - Premedications & Post-Medications For Patients With r/r FL Or r/r DLBCL
Table 6-35: Ordspono - Recommendations For Management Of Cytokine Release Syndrome
Table 6-36: Ziihera - Dosage Modifications For Adverse Reactions
Table 6-37: Bizengri - Premedications Prior To Infusions
Table 6-38: Bizengri - Premedications Prior to Infusions
Table 6-39: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
Table 6-40: Korjuny - Dosing Schedule
Table 6-41: Lynozyfic - Dosing Schedule
Table 6-42: Lynozyfic - Recommendations for Restarting Therapy After a Dose Delay

List Of Figures

LIST OF FIGURES

Figure 3-1: Global – Annual Multispecific Antibody Market (US$ Million), 2020-2026
Figure 3-2: Global - Annual Multispecific Antibodies Market By Drugs (US$ Million), Q1’2026
Figure 3-3: Global - Multispecific Antibodies Market Shares By Drugs (%), Q1’2026
Figure 3-4: Global - Annual Multispecific Antibodies Market By Drugs (US$ Million), 2025
Figure 3-5: Global - Multispecific Antibodies Market Shares By Drugs (%), 2025
Figure 3-6: Global - Annual Multispecific Antibody Market By Region (US$ Million), Q1’2026
Figure 3-7: Global – Multispecific Antibody Market Shares By Region (%), Q1’2026
Figure 3-8: Global – Quarterly Multispecific Antibody Market (US$ Million), 2025
Figure 3-9: Global - Annual Multispecific Antibody Market By Region (US$ Million), 2025
Figure 3-10: Global – Multispecific Antibody Market Shares By Region (%), 2025
Figure 3-11: US – Multispecific Antibody Market (US$ Million), 2020-2025
Figure 3-12: US - Quarterly Multispecific Antibodies Market (US$ Million), 2025
Figure 3-13: ROW – Multispecific Antibody Market Value (US$ Million), 2020-2025
Figure 3-14: ROW - Quarterly Multispecific Antibodies Market (US$ Million), 2025
Figure 3-15: Global - Multispecific Antibody Market Opportunity Assessment (US$ Billion), 2026 – 2031
Figure 3-16: Multiclonics - Distinctive Characteristics
Figure 3-17: Biclonics - Format
Figure 3-18: ADAPTIR Bispecific Structure
Figure 3-19: ADAPTIR-FLEX
Figure 3-20: BEAT Platform - Multispecific Antibodies
Figure 3-21: FIT-Ig - Proprietary Bispecific Platform
Figure 3-22: BiClone format
Figure 3-23: BioAtla CABs – Features
Figure 3-24: BioAtla CABs – Benefits
Figure 3-25: IMBiologic Bispecific Antibodies - Strategy
Figure 3-26: IMBiologic Bispecific Antibodies – Mechanism Of Action
Figure 3-27: Novel HBICE
Figure 3-28: HBICE - Mechanism Of Action 1
Figure 3-29: HBICE - Mechanism Of Action 2

Figure 3-30: Phanes Therapeutics – PACbody Platform
Figure 3-31: Phanes Therapeutics – SPECpair Platform
Figure 3-32: Phanes Therapeutics – ATACCbody
Figure 3-33: Numab Therapeutics - Technology
Figure 3-34: Grabody I Platform - Mechanism Of Action
Figure 3-35: Grabody I Platform - Mechanism Of Action
Figure 3-36: 3-Step DuoBody Production Process
Figure 3-37: DuoHexaBody Molecules – Schematic
Figure 3-38: iTAb – Patented Structure
Figure 3-39: iTAb – Mechanism of Action
Figure 3-40: Synimmune - Proprietary Bispecific Antibody Format
Figure 3-41: BiTE - Structure
Figure 3-42: BiTE Molecule
Figure 3-43: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 3-44: ALiCE – Characteristics
Figure 3-45: ALiCE - Schematic Diagram & Mechanism Of Action
Figure 3-46: Abz2 Bispecific Platform
Figure 3-47: Abz2 Bispecifics - Benefits
Figure 3-48: Neo-X-Prime Bispecific Mechanism
Figure 3-49: B-Body Bispecific Antibody - Structre
Figure 3-50: xLinkBsAb - Structure
Figure 3-51: PrecisionGATE Bispecific Antibody - Structure
Figure 3-52: Chugai Pharmaceutical - Dual-Ig Platform
Figure 3-53: EVOLVE Molecule
Figure 3-54: CD3-only Bispecifics vs. EVOLVE Trispecific Molecules
Figure 3-55: MabWorks - Multispecific Antibody Platform’s T-cell engagers
Figure 3-56: MabWorks - Multispecific Antibody Platform’s Immune-stimulatory multispecific antibodies
Figure 3-57: Marengo - TriSTAR
Figure 3-58: Merus – Multiclonics Antibodies
Figure 3-59: Merus – Triclonics Platform
Figure 3-60: Must Bio - BICSTA
Figure 3-61: Purple Biotech - CAPTN-3
Figure 3-62: Shine-On BioMedical - Trispecific T Cell Engager Antibody
Figure 3-63: Zymeworks Azymetric
Figure 3-64: DARPin Platform - Molecular Partners

Figure 3-65: ANKET® Platform - Innate Pharma
Figure 3-66: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 3-67: STEALTH – ModeX Therapeutics
Figure 3-68: MSTAR – ModeX Therapeutics
Figure 3-69: MSTAR – Salient Features
Figure 3-70: TECAD – QLSF Biotherapeutics
Figure 3-71: Multispecific VHH Antibody Drug Platform - Beijing StarMab Biomed Technology

Figure 4-1: LINKER-MM1 Phase I/II (NCT03761108) Study – Initiation & Completion Year
Figure 4-2: ELM-2 Phase II (NCT03888105) Study – Initiation & Completion Year
Figure 4-3: OLYMPIA-1 Phase III (NCT06091254) Study – Initiation & Completion Year
Figure 4-4: CPIT565A12101 Phase I (NCT05397496) Study – Initiation & Completion Year
Figure 4-5: CR109234 Phase I (NCT05652335) Study – Initiation & Completion Year
Figure 4-6: GNC-038-102 Phase I/II (NCT05192486) Study – Initiation & Completion Year
Figure 4-7: GNC-038-103 Phase I/II (NCT05485753) Study – Initiation & Completion Year
Figure 4-8: MDX-2003-101 Phase I/II (NCT07249905) Study – Initiation & Completion Year
Figure 4-9: CIBI3003A101 Phase I/II (NCT06083207) Study – Initiation & Completion Year
Figure 4-10: LBL-024-CN001 Phase I/II (NCT05170958) Study – Initiation & Completion Year
Figure 4-11: LBL-024-CN002 Phase I/II (NCT06157827) Study – Initiation & Completion Year
Figure 4-12: COMPANION-002 Phase II/III (NCT05506943) Study – Initiation & Completion Year
Figure 4-13: NbTAST-01 Phase I/II (NCT07055594) Study – Initiation & Completion Year
Figure 4-14: GNC-039-101 Phase I (NCT04794972) Study – Initiation & Completion Year
Figure 4-15: PM8002-BC011C-SCLC-R Phase II (NCT05844150) Study – Initiation & Completion Year

Figure 4-16: HARMONi-6 Phase III (NCT05840016) Study – Initiation & Completion Year
Figure 4-17: HARMONi-2 Phase III (NCT05499390) Study – Initiation & Completion Year
Figure 4-18: HARMONi-3 Phase I/II (NCT05899608) Study – Initiation & Completion Year
Figure 4-19: EMB01X201 Phase I/II (NCT05176665) Study – Initiation & Completion Year
Figure 4-20: AHAEmi Phase II (NCT05345197) Study – Initiation & Completion Year
Figure 4-21: BCDI-XII Phase I (NCT05500807) Study – Initiation & Completion Year
Figure 4-22: CL-101 Phase I/II (NCT06211634) Study – Initiation & Completion Year
Figure 4-23: HMB-001-201 Phase II (NCT07347249) Study – Initiation & Completion Year
Figure 4-24: YBSW015 Phase I (NCT05369754) Study – Initiation & Completion Year
Figure 4-25: CLN-978-SL-101 Phase I (NCT06613360) Study – Initiation & Completion Year
Figure 4-26: BBT001-001 Phase I (NCT06808477) Study – Initiation & Completion Year
Figure 4-27: BBT001-002 Phase I (NCT07239947) Study – Initiation & Completion Year
Figure 4-28: BBT002-001 Phase I (NCT06944925) Study – Initiation & Completion Year
Figure 4-29: BBT002-002 Phase I (NCT07288554) Study – Initiation & Completion Year
Figure 4-30: BBT002-003 Phase I (NCT07436949) Study – Initiation & Completion Year
Figure 4-31: BCDI-XII Phase I (NCT05500807) Study – Initiation & Completion Year
Figure 4-32: BRUNELLO Phase II/III (NCT06571045) Study – Initiation & Completion Year
Figure 4-33: BAROLO Phase II/III (NCT06957080) Study – Initiation & Completion Year
Figure 4-34: MALBEC Phase II/III (NCT06957080) Study – Initiation & Completion Year
Figure 4-35: ASKG712-CT-I-1 Phase I (NCT05456828) Study – Initiation & Completion Year

Figure 5-1: US – Approved Multispecific Antibodies
Figure 5-2: EU – Approved Multispecific Antibodies

Figure 6-1: Blincyto – Approval Year By Region
Figure 6-2: Blincyto – Patent Filing & Expiration Year
Figure 6-3: Blincyto - Treatment Regimen Cycles (Weeks)


Figure 6-4: Blincyto – Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
Figure 6-5: Blincyto – Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
Figure 6-6: Blincyto – Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-7: Hemlibra – Approval Years By Region
Figure 6-8: Hemlibra – Cost Per Unit & Supply Of 30 mg/mL Subcutaneous Injection By Volume (US$), May’2026
Figure 6-9: Hemlibra – Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), May’2026
Figure 6-10: Hemlibra – Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
Figure 6-11: Rybrevant – Patent Filing & Expiration Year
Figure 6-12: Rybrevant – Price Per Unit & Supply Of Intravenous Solution (US$), May’2026
Figure 6-13: Rybrevant – Recommended Dose Per Cycle By Body Weight (mg)
Figure 6-14: Rybrevant – Dose Reduction In Patients With Weight Less Than 80 kg (mg)
Figure 6-15: Rybrevant – Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 6-16: Vabysmo – Approval Year By Region
Figure 6-17: Rybrevant – Patent Filing & Expiration Year
Figure 6-18: Vabysmo – Price Per Unit & Supply Of Intravitreal Solution (US$), May’2026
Figure 6-19: Lunsumio – Approval Years By Region
Figure 6-20: US – Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), May’2026
Figure 6-21: EU – Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), May’2026
Figure 6-22: Tecvayli – Approval Years by Region
Figure 6-23: Tecvayli – Patent Acceptance & Expiration Year
Figure 6-24: US – Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), May’2026
Figure 6-25: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), May’2026
Figure 6-26: Columvi – Approval Year By Region

Figure 6-27: US – Price Per Unit & Supply Of Columvi Intravenous Solution (US$), May’2026
Figure 6-28: EU – Price Of Supply Of Columvi Intravenous Solution (US$), May’2026
Figure 6-29: Epkinly – Approval Year By Region
Figure 6-30: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), May’2026
Figure 6-31: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), May’2026
Figure 6-32: Talvey – Approval Year By Region
Figure 6-33: Talquetamab – FDA & EMA Designation Year
Figure 6-34: Talvey – Patent Acceptance & Expiration Year
Figure 6-35: US – Price Per Unit & Supply Of Talvey Intravenous Solution (US$), May’2026
Figure 6-36: EU – Price Per Supply Of Talvey Intravenous Solution (US$), May’2026
Figure 6-37: Elrexfio – Approval Year by Region
Figure 6-38: Elranatamab – FDA & EMA Designation Year
Figure 6-39: US – Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), May’2026
Figure 6-40: Imdelltra – Approval Year By Region
Figure 6-41: US – Price Of Supply Of Imdelltra Intravenous Powder (US$), May’2026
Figure 6-42: EU – Price Of Supply Of Imdelltra Intravenous Powder (US$), May’2026
Figure 6-43: EU – Price Of Supply Of Ordspono Intravenous Powder (US$), May’2026
Figure 6-44: US & EU – Price Per Unit & Supply Of Ziihera (US$), May’2026
Figure 6-45: Zenocutuzumab – Active Patents
Figure 6-46: US – Price Of Supply Of Bizengri Intravenous Solution (US$), May’2026
Figure 6-47: US – Price Per Unit & Supply of Lynozyfic Intravenous Solution, May’2026
Figure 6-48: Global – Blincyto Sales (US$ Million), 2020–2026
Figure 6-49: Global – Blincyto Quarterly Sales (US$ Million), 2025
Figure 6-50: US – Blincyto Sales (US$ Million), 2020-2026
Figure 6-51: US – Blincyto Quarterly Sales (US$ Million), 2025
Figure 6-52: ROW – Blincyto Sales (US$ Million), 2020-2026
Figure 6-53: ROW – Blincyto Quarterly Sales (US$ Million), 2025
Figure 6-54: Global – Hemlibra Sales (US$ Million), 2020-2026
Figure 6-55: Global – Hemlibra Quarterly Sales (US$ Million), 2025
Figure 6-56: Global – US v/s ROW Sales (US$ Million), Q1’2026
Figure 6-57: Global – US v/s ROW Sales (US$ Million), 2025

Figure 6-58: Global – Hemlibra Sales By Region (US$ Million), Q1’2026
Figure 6-59: Global – Hemlibra Sales By Region (US$ Million), 2025
Figure 6-60: Global – Hemlibra Sales By Region (%), Q12026
Figure 6-61: Global – Hemlibra Sales By Region (%), 2025
Figure 6-62: US – Hemlibra Sales (US$ Million), 2020-2026
Figure 6-63: US – Hemlibra Quarterly Sales (US$ Million), 2025
Figure 6-64: Europe – Hemlibra Sales (US$ Million), 2020-2026
Figure 6-65: Europe – Hemlibra Quarterly Sales (US$ Million), 2025
Figure 6-66: Japan – Hemlibra Sales (US$ Million), 2020-2026
Figure 6-67: Japan – Hemlibra Quarterly Sales (US$ Million), 2025
Figure 6-68: ROW – Hemlibra Sales (US$ Million), 2020-2026
Figure 6-69: ROW – Hemlibra Quarterly Sales (US$ Million), 2025
Figure 6-70: Global – Rybrevant Sales (US$ Million), 2024–2026
Figure 6-71: Global – Rybrevant Quarterly Sales (US$ Million), 2025
Figure 6-72: US – Rybrevant Sales ((US$ Million), 2024-2026
Figure 6-73: US – Rybrevant Quarterly Sales (US$ Million), 2025
Figure 6-74: ROW – Rybrevant Sales (US$ Million), 2024-2026
Figure 6-75: ROW – Rybrevant Quarterly Sales (US$ Million), 2025
Figure 6-76: Global – Vabysmo Sales (US$ Million), 2022-2026
Figure 6-77: Global – Vabysmo Quarterly Sales (US$ Million), 2025
Figure 6-78: Global – US v/s ROW Sales (US$ Million), Q1’2026
Figure 6-79: Global – US v/s ROW Sales (US$ Million), 2025
Figure 6-80: Global – Vabysmo Sales By Region (US$ Million), Q1’2026
Figure 6-81: Global – Vabysmo Sales By Region (US$ Million), 2025
Figure 6-82: Global – Vabysmo Sales By Region (%), Q1’2026
Figure 6-83: Global – Vabysmo Sales By Region (%), 2025
Figure 6-84: US – Vabysmo Sales (US$ Million), 2022-2026
Figure 6-85: US – Vabysmo Quarterly Sales (US$ Million), 2025
Figure 6-86: Europe – Vabysmo Sales (US$ Million), 2022-2026
Figure 6-87: Europe – Vabysmo Quarterly Sales (US$ Million), 2025
Figure 6-88: Japan – Vabysmo Sales (US$ Million), 2022-2026
Figure 6-89: Japan – Vabysmo Quarterly Sales (US$ Million), 2025
Figure 6-90: ROW – Vabysmo Sales (US$ Million), 2022-2026
Figure 6-91: ROW – Vabysmo Quarterly Sales (US$ Million), 2025
Figure 6-92: Global – Lunsumio Sales (US$ Million), 2022-2025
Figure 6-93: Global – Lunsumio Quarterly Sales (US$ Million), 2025

Figure 6-94: Global – US v/s ROW Sales (US$ Million), Q1’2026
Figure 6-95: Global – US v/s ROW Sales (US$ Million), 2025
Figure 6-96: Global – Lunsumio Sales By Region (US$ Million), Q1’2026
Figure 6-97: Global – Lunsumio Sales By Region (US$ Million), 2025
Figure 6-98: Global – Lunsumio Sales By Region (%), Q1’2026
Figure 6-99: Global – Lunsumio Sales By Region (%), 2025
Figure 6-100: US – Lunsumio Sales (US$ Million), 2022-2026
Figure 6-101: US – Lunsumio Quarterly Sales (US$ Million), 2025
Figure 6-102: Europe – Lunsumio Sales (US$ Million), 2022-2026
Figure 6-103: Europe – Lunsumio Quarterly Sales (US$ Million), 2025
Figure 6-104: Japan – Lunsumio Sales (US$ Million), 2022-2026
Figure 6-105: Japan – Lunsumio Quarterly Sales (US$ Million), 2025
Figure 6-106: ROW – Lunsumio Sales (US$ Million), 2022-2026
Figure 6-107: ROW – Lunsumio Quarterly Sales (US$ Million), 2025
Figure 6-108: China – Kaitani Sales (US$ Million), 2022-2023
Figure 6-109: Global – Tecvayli Sales (US$ Million), 2022-2026
Figure 6-110: Tecvayli - US v/s ROW Sales (US$ Million), Q1’2025
Figure 6-111: Tecvayli - US v/s ROW Sales (US$ Million), 2025
Figure 6-112: Tecvayli - US v/s ROW Sales (%), Q1’2026
Figure 6-113: Tecvayli - US v/s ROW Sales (%), 2025
Figure 6-114: Global – Tecvayli Quarterly Sales (US$ Million), 2025
Figure 6-115: US – Tecvayli Sales (US$ Million), 2022-2026
Figure 6-116: US – Tecvayli Quarterly Sales (US$ Million), 2025
Figure 6-117: ROW – Tecvayli Sales (US$ Million), 2022-2026
Figure 6-118: ROW – Tecvayli Quarterly Sales (US$ Million), 2025
Figure 6-119: Global – Columvi Sales (US$ Million), 2023-2026
Figure 6-120: Global – Columvi Quarterly Sales (US$ Million), 2025
Figure 6-121: Global – US v/s ROW Sales (US$ Million), Q1’2026
Figure 6-122: Global – US v/s ROW Sales (US$ Million), 2025
Figure 6-123: Global – Columvi Sales By Region (US$ Million), Q1’2026
Figure 6-124: Global – Columvi Sales By Region (US$ Million), 2025
Figure 6-125: Global – Columvi Sales By Region (%), Q1’2026
Figure 6-126: Global – Columvi Sales By Region (%), 2025
Figure 6-127: US – Columvi Sales (US$ Million), 2023-2026
Figure 6-128: US – Columvi Quarterly Sales (US$ Million), 2025
Figure 6-129: Europe – Columvi Sales (US$ Million), 2023-2026

Figure 6-130: Europe – Columvi Quarterly Sales (US$ Million), 2025
Figure 6-131: ROW – Columvi Sales (US$ Million), 2023-2026
Figure 6-132: ROW – Columvi Quarterly Sales (US$ Million), 2025
Figure 6-133: Global – Epkinly Sales (US$ Million), 2023-2026
Figure 6-134: Global – Epkinly Sales Reported By Genmab (US$ Million), 2023-2026
Figure 6-135: Global – Epkinly Sales Reported By AbbVie (US$ Million), 2023-2026
Figure 6-136: Global – Epkinly Quarterly Sales (US$ Million), 2025
Figure 6-137: Global – Talvey Sales (US$ Million), 2024–2026
Figure 6-138: Global – Talvey Quarterly Sales (US$ Million), 2025
Figure 6-139: US – Talvey Sales ((US$ Million), 2024-2026
Figure 6-140: US – Talvey Quarterly Sales (US$ Million), 2025
Figure 6-141: ROW – Talvey Sales (US$ Million), 2024-2026
Figure 6-142: ROW – Talvey Quarterly Sales (US$ Million), 2025
Figure 6-143: Global – Elrexfio Sales (US$ Million), 2023-2026*
Figure 6-144: Global – Elrexfio Quarterly Sales (US$ Million), 2025
Figure 6-145: US – Elrexfio Sales (US$ Million), 2023-2026
Figure 6-146: Global – Elrexfio Quarterly Sales (US$ Million), 2025
Figure 6-147: ROW – Elrexfio Sales (US$ Million), 2023-2026
Figure 6-148: Global – Elrexfio Quarterly Sales (US$ Million), 2025
Figure 6-149: Global – Imdelltra Sales (US$ Million), 2024-2026
Figure 6-150: Global – Imdelltra Quarterly Sales (US$ Million), 2025
Figure 6-151: US – Imdelltra Sales ((US$ Million), 2024-2026
Figure 6-152: US – Imdelltra Quarterly Sales (US$ Million), 2025
Figure 6-153: ROW – Imdelltra Sales (US$ Million), 2024-2026
Figure 6-154: ROW – Imdelltra Quarterly Sales (US$ Million), 2025
Figure 6-155: Global – Ordspono Sales (US$ Million), 2026
Figure 6-156: Global – Ziihera Sales (US$ Million), 2024-2026
Figure 6-157: Global – Ziihera Quarterly Sales (US$ Million), 2025
Figure 6-158: Global – Lynozyfic Sales (US$ Million), 2026

Figure 7-1: Global – Number of Bispecific Antibodies In Clinical Pipeline By Phase, 2026 Till 2031
Figure 7-2: Global – Number Of Trispecific Antibodies Clinical Trials By Company, 2026
Figure 7-3: Global – Number Of Trispecific Antibodies Clinical Trials By Country, 2026

Figure 7-4: Global – Number Of Trispecific Antibodies Clinical Trials By Indications, 2026
Figure 7-5: Global – Number Of Trispecific Antibodies Clinical Trials By Phase, 2026
Figure 7-6: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2026
Figure 7-7: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2026
Figure 7-8: Global – Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2026
Figure 7-9: Global – Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2026